ClinicalTrials.gg
CompletedNCT00922779Updated Jan 20, 2016Results posted

A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] and ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 93 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-20.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,661
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
Largest of 83
6,661 · median 129
Started
2002
with 3 others
Phase 4
48 of 83
none open now
Registered
50th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one has the largest enrollment, is one of 4 that started in 2002, is one of 48 in phase 4, and was the 50th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This single arm study will evaluate the safety and tolerability of ribavirin in combination with PEGASYS in patients with chronic hepatitis C. Patients will receive ribavirin 800mg, or 1000-1200mg po daily, according to HCV genotype and body weight (\< and >75kg)in combination with PEGASYS 180micrograms sc weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is >500 individuals.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • serological evidence of chronic ;
  • detectable serum HCV-RNA;
  • liver findings consistent with a diagnosis of chronic hepatitis C.

Exclusion criteria

Exclusion Criteria:

  • history or other evidence of a medical condition associated with chronic liver disease other than ;
  • co-infection with active hepatitis A or B;
  • hepatocellular carcinoma;
  • patients with severe cardiovascular disease whose condition may worsen due to acute anemia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6,661 participants (actual)

Study arms

  • Experimental
    1

    Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants with non-serious AEs were exclusive of serious AEs.

    Time frame: From signing of informed consent up to end of study (up to Week 72)

Secondary outcomes

  1. Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Therapy

    SVR at 24 weeks after end of therapy was defined as a negative result of HCV Ribonucleic Acid (HCV RNA) qualitative assay 24 weeks after end of therapy. Percentage of participants with SVR was calculated as \[number of participants with negative results of HCV RNA qualitative assay 24 weeks after end of therapy divided by the total number of participants analyzed\] multiplied by 100. The participants who failed to undergo tests at 24 weeks after completion of therapy were considered not amenable to therapy.

    Time frame: 24 weeks after end of therapy (Week 72)

  2. Percentage of Participants With Undetectable HCV RNA at Weeks 12, 24 and 48 After Therapy Initiation

    HCV RNA levels of \< 50 International Units per milliliter (IU/mL) were defined as undetectable HCV RNA. The percentage of participants with undetectable HCV RNA was calculated as \[number of participants with undetectable HCV RNA divided by the total number of participants analyzed\] multiplied by 100 for Weeks 12, 24 and 48.

    Time frame: Weeks 12,24 and 48 After Therapy Initiation

  3. Percentage of Participants With Change in Hemoglobin Level

    Change in hemoglobin level (compared to baseline) was reported as "significant decrease", "Normal" (no change), "Increase", "Decrease", and "Missing". Significant decrease was defined as per Investigator's discretion.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 48 and follow-up Weeks 4 (Week 52), 12 (Week 60), and 24 (Week 72)

07

Results

Posted Jan 20, 2016

Participant flow

A total of 7799 participants were screened, of which 6661 participants were included in the study.

Participant flow — Overall Study
MilestoneRibavirin + Peginterferon Alfa-2a
Started6661
Completed4334
Not completed2327
Withdrew: Adverse event67
Withdrew: Pregnancy7
Withdrew: Withdrawal by subject308
Withdrew: Lost to follow-up44
Withdrew: Other27
Withdrew: Missing1874

Outcome measures

PrimaryNumber of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants with non-serious AEs were exclusive of serious AEs.

Time frame:
From signing of informed consent up to end of study (up to Week 72)
Reported as:
Number · Participants
Number of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs)
ParticipantsRibavirin + Peginterferon Alfa-2a
Non Serious AEs2058
SAEs67
SecondaryPercentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Therapy

SVR at 24 weeks after end of therapy was defined as a negative result of HCV Ribonucleic Acid (HCV RNA) qualitative assay 24 weeks after end of therapy. Percentage of participants with SVR was calculated as \[number of participants with negative results of HCV RNA qualitative assay 24 weeks after end of therapy divided by the total number of participants analyzed\] multiplied by 100. The participants who failed to undergo tests at 24 weeks after completion of therapy were considered not amenable to therapy.

Time frame:
24 weeks after end of therapy (Week 72)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Therapy
Percentage of ParticipantsRibavirin + Peginterferon Alfa-2a
Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Therapy50.9
SecondaryPercentage of Participants With Undetectable HCV RNA at Weeks 12, 24 and 48 After Therapy Initiation

HCV RNA levels of \< 50 International Units per milliliter (IU/mL) were defined as undetectable HCV RNA. The percentage of participants with undetectable HCV RNA was calculated as \[number of participants with undetectable HCV RNA divided by the total number of participants analyzed\] multiplied by 100 for Weeks 12, 24 and 48.

Time frame:
Weeks 12,24 and 48 After Therapy Initiation
Reported as:
Number · Percentage of Participants
Percentage of Participants With Undetectable HCV RNA at Weeks 12, 24 and 48 After Therapy Initiation
Percentage of ParticipantsRibavirin + Peginterferon Alfa-2a
Week 1258.8
Week 2469.7
Week 4824.8
SecondaryPercentage of Participants With Change in Hemoglobin Level

Change in hemoglobin level (compared to baseline) was reported as "significant decrease", "Normal" (no change), "Increase", "Decrease", and "Missing". Significant decrease was defined as per Investigator's discretion.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, 48 and follow-up Weeks 4 (Week 52), 12 (Week 60), and 24 (Week 72)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Change in Hemoglobin Level
Percentage of ParticipantsRibavirin + Peginterferon Alfa-2a
Week 2, Significant decrease13.5
Week 2, Normal32.4
Week 2, Increase11.7
Week 2, Decrease32.3
Week 2, Missing10.0
Week 4, Significant decrease27.9
Week 4, Normal21.0
Week 4, Increase6.9
Week 4, Decrease35.1
Week 4, Missing9.1
Week 8, Significant decrease35.4
Week 8, Normal15.3
Week 8, Increase5.1
Week 8, Decrease31.5
Week 8, Missing12.8
Week 12, Significant decrease38.9
Week 12, Normal15.2
Week 12, Increase4.7
Week 12, Decrease30.1
Week 12, Missing11.1
Week 24, Significant decrease34.9
Week 24, Normal13.6
Week 24, Increase4.6
Week 24, Decrease25.4
Week 24, Missing21.5
Week 36, Significant decrease16.2
Week 36, Normal4.1
Week 36, Increase1.7
Week 36, Decrease9.1
Week 36, Missing69.0
Week 48, Significant decrease13.7
Week 48, Normal3.8
Week 48, Increase1.7
Week 48, Decrease7.7
Week 48, Missing73.1
Follow-up Week 4, Significant decrease11.5
Follow-up Week 4, Normal18.5
Follow-up Week 4, Increase6.8
Follow-up Week 4, Decrease19.6
Follow-up Week 4, Missing43.7
Follow-up Week 12, Significant decrease5.8
Follow-up Week 12, Normal23.0
Follow-up Week 12, Increase10.2
Follow-up Week 12, Decrease16.1
Follow-up Week 12, Missing44.8
Follow-up Week 24, Significant decrease4.7
Follow-up Week 24, Normal27.5
Follow-up Week 24, Increase12.2
Follow-up Week 24, Decrease15.5
Follow-up Week 24, Missing40.2

Adverse events

Collected over From signing of informed consent up to end of study (up to Week 72). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ribavirin + Peginterferon Alfa-2a—67/6,661 (1%)1,674/6,661 (25.1%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventRibavirin + Peginterferon Alfa-2a
Pyelonephritis acuteInfections and infestations2/6661
CholecystitisHepatobiliary disorders2/6661
CholelithiasisHepatobiliary disorders2/6661
Hepatic cirrhosisHepatobiliary disorders2/6661
Hepatic failureHepatobiliary disorders2/6661
Myocardial infarctionCardiac disorders2/6661
Completed suicidePsychiatric disorders2/6661
DepressionPsychiatric disorders2/6661
AstheniaGeneral disorders2/6661
Toxic skin eruptionSkin and subcutaneous tissue disorders2/6661
Most frequent other events
Most frequent other events
EventRibavirin + Peginterferon Alfa-2a
AstheniaGeneral disorders905/6661
Influenza like illnessGeneral disorders833/6661
AnaemiaBlood and lymphatic system disorders459/6661
PyrexiaGeneral disorders371/6661
Weight loss poorMetabolism and nutrition disorders343/6661

Baseline characteristics

Baseline population included all enrolled participants.

Age, Continuous
Age, Continuous(Years)Ribavirin + Peginterferon Alfa-2a
Mean34.21 ± 9.81
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Ribavirin + Peginterferon Alfa-2a
Male4396
Female2250
Missing15
08

Study locations

93 sites
  • Arkhangelsk, 163000, Russian Federation
  • Barnaul, 656010, Russian Federation
  • Barnaul, 656045, Russian Federation
  • Blagoveshchensk, 675007, Russian Federation
  • Cheboksary, 428016, Russian Federation
  • Chelyabinsk, 454048, Russian Federation
  • Chelyabinsk, 454052, Russian Federation
  • Chelyabinsk, 454071, Russian Federation
  • Cherepovets, 162600, Russian Federation
  • Chita, 672090, Russian Federation
  • Ekaterinburg, 620020, Russian Federation
  • Ekaterinburg, 620042, Russian Federation
  • Ekaterinburg, 620102, Russian Federation
  • Irkutsk, 664043, Russian Federation
  • Irkutsk, 664047, Russian Federation
  • Irkutsk, 664079, Russian Federation
  • Izhevsk, 426067, Russian Federation
  • Kazan, 420097, Russian Federation
  • Kemerovo, 650000, Russian Federation
  • Kemerovo, 650036, Russian Federation
  • Kemerovo, 650099, Russian Federation
  • Khabarovsk, 680009, Russian Federation
  • Khabarovsk, 680022, Russian Federation
  • Khabarovsk, 680031, Russian Federation
  • Kirov, 610000, Russian Federation
  • Krasnodar, 350012, Russian Federation
  • Krasnodar, 350015, Russian Federation
  • Krasnodar, 350086, Russian Federation
  • Krasnoyarsk, 660022, Russian Federation
  • Krasnoyarsk, 660049, Russian Federation
  • Lipetsk, 398043, Russian Federation
  • Makhachkala, 367008, Russian Federation
  • Moscow, 103875, Russian Federation
  • Moscow, 105203, Russian Federation
  • Moscow, 109325, Russian Federation
  • Moscow, 111020, Russian Federation
  • Moscow, 111123, Russian Federation
  • Moscow, 115201, Russian Federation
  • Moscow, 115446, Russian Federation
  • Moscow, 115516, Russian Federation
  • Moscow, 115682, Russian Federation
  • Moscow, 119002, Russian Federation
  • Moscow, 119881, Russian Federation
  • Moscow, 121293, Russian Federation
  • Moscow, 123098, Russian Federation
  • Moscow, 123367, Russian Federation
  • Moscow, 125101, Russian Federation
  • Moscow, 125367, Russian Federation
  • Moscow, 127247, Russian Federation
  • Moscow, 129110, Russian Federation
  • Moscow, 143420, Russian Federation
  • Moscow, Russian Federation
  • Nizhny Novgorod, 603022, Russian Federation
  • Novokuznetsk, 654018, Russian Federation
  • Novokuznetsk, 654029, Russian Federation
  • Novosibirsk, 630016, Russian Federation
  • Novouralsk, 624130, Russian Federation
  • Omsk, 644010, Russian Federation
  • Orenburg, 460035, Russian Federation
  • Petropavlovsk-Kamchatskiy, 683003, Russian Federation
  • Rostov-na-donu, 344022, Russian Federation
  • Salekhard, 629001, Russian Federation
  • Samara, 443011, Russian Federation
  • Samara, 443021, Russian Federation
  • Saratov, 410026, Russian Federation
  • Saratov, 410028, Russian Federation
  • Saratov, 410040, Russian Federation
  • Soshi, 354057, Russian Federation
  • St Petersburg, 194044, Russian Federation
  • St Petersburg, 194291, Russian Federation
  • St Petersburg, 195067, Russian Federation
  • St Petersburg, 195275, Russian Federation
  • St Petersburg, 197022, Russian Federation
  • St Petersburg, 198103, Russian Federation
  • St Petersburg, 199034, Russian Federation
  • St. Petersburg, 191167, Russian Federation
  • Stavropol, 355017, Russian Federation
  • Surgut, 628400, Russian Federation
  • Tjumen, 629806, Russian Federation
  • Tomsk, 634050, Russian Federation
  • Tumen, 625002, Russian Federation
  • Tumen, 625017, Russian Federation
  • Tumen, 625026, Russian Federation
  • UFA, 450000, Russian Federation
  • UFA, 450005, Russian Federation
  • Ulan-ude, 670042, Russian Federation
  • Vladivostok, 690011, Russian Federation
  • Vladivostok, 690065, Russian Federation
  • Volgograd, 400040, Russian Federation
  • Volgograd, 400138, Russian Federation
  • Yakutsk, 677000, Russian Federation
  • Yujno-sakhalinsk, 690000, Russian Federation
  • Yujno-sakhalinsk, 693000, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2009
First posted
Jun 17, 2009
Start
Jun 2002
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Jan 20, 2016
Last update
Jan 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00922779
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 17, 2009
Start date
Jun 2002
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Jan 20, 2016
Last update
Jan 20, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion